Business Context and Reporting Period
Oramed Pharmaceuticals Inc. (ORMP) filed this Form 8-K on September 18, 2020, reporting an event that occurred on September 16, 2020. The Company is a Delaware corporation with principal executive offices in New York, New York. Its common stock trades on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to a new contractual commitment:
- Contract Value: Up to approximately $12.3 million.
- Payment Terms: Payments are contingent upon the achievement of certain milestones over the term of the engagement.
Material Changes
The material change reported is the entry into a Material Definitive Agreement. On September 16, 2020, Oramed Ltd., a wholly-owned subsidiary, entered into an additional Clinical Research Organization (CRO) Services Agreement with Integrium, LLC. This agreement is effective as of January 15, 2020, and covers the U.S. portion of the Company's planned upcoming Phase 3 clinical trial for ORMD-0801.
Outlook, Risks, and Management Commentary
Clinical Trial Scope: The agreement supports a Phase 3 trial designed to assess the safety and efficacy of ORMD-0801 in approximately 600 type 2 diabetic patients. The trial is conducted under an Investigational New Drug application with the U.S. Food and Drug Administration.
Agreement Terms: The agreement will terminate upon the satisfactory performance of all services. Certain information regarding the agreement was excluded from the public exhibit as it was deemed not material but potentially competitively harmful if disclosed.
Key Facts for Investor Verification
- Verify the specific milestones required to trigger the $12.3 million payment to Integrium, LLC.
- Confirm the current status and enrollment progress of the Phase 3 clinical trial for ORMD-0801.
- Review the Company's cash reserves to ensure sufficient liquidity to fund the milestone payments as they come due.
- Monitor FDA communications regarding the Investigational New Drug application for the trial.